Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H12O3 |
Molecular Weight | 228.2433 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)C(=O)OCC2=CC=CC=C2
InChI
InChIKey=MOZDKDIOPSPTBH-UHFFFAOYSA-N
InChI=1S/C14H12O3/c15-13-8-6-12(7-9-13)14(16)17-10-11-4-2-1-3-5-11/h1-9,15H,10H2
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23220609 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Oestrogenic activity of benzylparaben. | 2003 Jan-Feb |
|
A review of the endocrine activity of parabens and implications for potential risks to human health. | 2005 Jun |
|
Optimisation of a solid-phase microextraction method for the determination of parabens in water samples at the low ng per litre level. | 2006 Aug 18 |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Metabolism of parabens (4-hydroxybenzoic acid esters) by hepatic esterases and UDP-glucuronosyltransferases in man. | 2010 |
Patents
Sample Use Guides
in mice (topical): of three daily doses of 33 mg to dorsal skin
in rats (intragastric): 0.16 mg/kg body up to 100 μg/kg body weight
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12518336
Benzylparaben was able to displace [(3)H]oestradiol from cytosolic oestrogen receptor (ER) of MCF7 human breast cancer cells by 22% at 1000-fold molar excess, by 40% at 10,000-fold molar excess, by 57% at 100 000-fold molar excess and by 100% at 1,000,000-fold molar excess. It was able to increase expression of a stably transfected oestrogen responsive reporter gene (ERE-CAT) in MCF7 cells after 24 h at 10(-5)M/10(-4)M and after 7 days at 10(-6)M/10(-5)M/10(-4)M. Proliferation of MCF7 cells could be increased by 10(-6)M/10(-5)M benzylparaben and this could be inhibited by 10(-7)M pure anti-oestrogen ICI 182,780, indicating that growth effects were ER mediated
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000185508
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
||
|
NCI_THESAURUS |
C92608
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C95327
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
8080
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
N0000184306
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
SUB13025MIG
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
8Y41DYV4VG
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
SUB61024
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
C057775
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
202-311-9
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
N0000171131
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
BENZYLPARABEN
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | Description: A white to creamy white, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; soluble in ethanol (~750 g/l) TS and ether R; dissolves in solutions of alkali hydroxides. Category: Antimicrobial preservative. Storage: Benzyl hydroxybenzoate should be kept in a well-closed container. Requirement: Benzyl hydroxybenzoate contains not less than 99.0% and not more than the equivalent of 101.0% of C14H12O3. | ||
|
7180
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
DB14176
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
94-18-8
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
N0000175629
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | Increased Histamine Release [PE] | ||
|
DTXSID9022526
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
8Y41DYV4VG
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
100000134265
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | |||
|
19075
Created by
admin on Fri Dec 15 15:51:28 GMT 2023 , Edited by admin on Fri Dec 15 15:51:28 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)